All articles tagged: Diffuse large B-cell lymphoma, unspecified site (C83.30)

Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress of the European Hematology Association, held from June 13 to 16 in Madrid.Jeremy Abramson, M.D., from the Massachusett

For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) yields durable remission, according to a study published in the June 20 issue of the New England Journal of Medicine.Christopher Melani, M.D., fro

Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England Journal of Medicine.Mark P. Hamilton, M.D., Ph.D., from Stanford University in California, and colleagues examined the occurrence of second tumors after CAR T-cell therapy since 2016.

University of Wisconsin–Madison researchers have uncovered a critical process driving resistance in certain types of lymphoma, offering hope for patients who become resistant to standard treatments. The study focused on understanding why some patients with B-cell malignancies, such as mantle cell lymphoma and diffuse large B-cell lymphoma, develop resistance to Bruton tyrosine kinase inhibitors (B

The FDA has granted accelerated approval for lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in certain adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Developed by Juno Therapeutics, the therapy, branded as Breyanzi, targets CD19 and is approved for patients who've undergone at least two prior lines of therapy, including specif

Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood Advances.Jee H. Choe, from the University of Southern California in Los Angeles, and colleagues evaluated the cost

The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and

For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year progression-free survival (PFS) of 28.5 percent and overall survival of 40.3 percent, according to a study presented at the annual

For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a study published online Dec. 5 in the Annals of Internal Medicine.Amar H. Kelkar, M.D., M.P.H., from the Dana-Farbe